VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
STLN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
STLNStarling Oncology, Inc.
$3.40$362M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksSTLNBalance Sheet

Starling Oncology, Inc. (STLN) Balance Sheet

7Y historyFree accessUpdated daily

Equity has deteriorated to -$24.9M from $41.3M in Q1 2024, while total debt fell to $24.6M but the current ratio dropped to 1.36, indicating increased short-term obligations.

Income StatementBalance SheetCash FlowRatios

STLN Balance Sheet

Annual statement

STLN Balance Sheet

Starling Oncology, Inc. (STLN) balance sheet — 7-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Total Current Assets137.69M112.75M112.42M143.49M130.42M154.06M29.72M21.79M
Cash & Short-Term Investments36.9M33.56M49.67M82.86M73.81M114.3M6M2.45M
Cash Only36.9M33.56M49.67M33.49M14.01M114.3M6M2.45M
Short-Term Investments00049.37M59.8M000
Accounts Receivable60.8M59.32M48.68M42.91M40.43M21.24M17.26M14.73M
Days Sales Outstanding36.2243.0745.1748.3158.4538.233.5934.61
Inventory36.63M16.88M10.04M13.68M9.26M6.44M4.35M3.89M
Days Inventory Outstanding23.6514.4510.818.8616.8714.4910.5511.31
Other Current Assets3.36M2.99M4.03M00875K00
Total Non-Current Assets50.08M51.91M60.3M65.75M131.25M49.38M35.97M37.73M
Property, Plant & Equipment32.57M33.06M37.67M40.05M33.04M4.19M2.1M1.55M
Fixed Asset Turnover19.00x15.21x10.44x8.10x7.64x48.43x89.12x100.20x
Goodwill7.23M7.23M7.23M7.23M21.42M26.63M14.23M14.08M
Intangible Assets8.87M11.02M14.81M17.9M17.96M18.25M19.52M22M
Long-Term Investments000058.35M-371K00
Other Non-Current Assets1.42M606K589K561K477K320K122K97.85K
Total Assets187.77M164.66M172.72M209.24M261.67M203.44M65.69M59.52M
Asset Turnover3.55x3.05x2.28x1.55x0.96x1.00x2.85x2.61x
Asset Growth %14.76%--17.46%-20.04%28.62%209.7%10.36%-
Total Current Liabilities123.7M70.96M52.22M34.79M29.72M29.8M28.61M13.59M
Accounts Payable82.09M43.17M24.32M14.43M9.37M15.56M12.64M8.89M
Days Payables Outstanding56.3836.9626.1619.917.0735.0230.6325.85
Short-Term Debt7.27M0000183K5.37M0
Deferred Revenue (Current)6.48M2.28M4.7M545K1.14M592K3.38M0
Other Current Liabilities116.43M13.15M10.35M11.32M9.35M10.14M-3.38M0
Current Ratio1.11x1.59x2.15x4.12x4.39x5.17x1.04x1.60x
Quick Ratio0.82x1.35x1.96x3.73x4.08x4.95x0.89x1.32x
Cash Conversion Cycle3.4920.5629.847.2758.2517.6713.5120.07
Total Non-Current Liabilities101.43M109.41M116.91M117.43M108.77M69.48M8.98M3.71M
Long-Term Debt17.94M77.4M93.13M86.83M80.62M06.56M0
Capital Lease Obligations55.36M19.13M23.22M26.49M22.06M000
Deferred Tax Liabilities0032K32K108K371K1.61M2.96M
Other Non-Current Liabilities83.49M12.88M527K4.08M5.98M69.11M807K756.42K
Total Liabilities225.13M180.38M169.13M152.22M138.49M99.28M37.59M17.3M
Total Debt25.21M103.69M123.15M119.67M108.18M183K11.93M0
Net Debt-11.69M70.12M73.48M86.19M94.17M-114.12M5.93M-2.45M
Debt / Equity-0.67x-34.31x2.10x0.88x0.00x0.42x-
Debt / EBITDA-1.75x-------
Net Debt / EBITDA0.81x-------8.23x
Interest Coverage-1.87x-4.39x-7.63x-8.88x-17.64x-141.82x-41.69x-780.67x
Total Equity-37.35M-15.72M3.59M57.02M123.17M104.16M28.1M42.22M
Equity Growth %-204.34%--93.71%-53.7%18.26%270.66%-33.45%-
Book Value per Share-0.04-0.170.050.771.531.570.480.66
Total Shareholders' Equity-37.35M-15.72M3.59M57.02M123.17M104.16M28.1M42.22M
Common Stock10K10K8K8K7K7K6K0
Retained Earnings-299.45M-271.42M-210.81M-146.15M-63.08M-63.23M-52.31M-6.02M
Treasury Stock0-1.02M-1.02M-1.02M0000
Accumulated OCI00000000
Minority Interest00000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrained
Balance SheetVulnerable
Cash FlowMixed
Top Statement Risk

Negative equity and high debt

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Equity Erosion Accelerates

TOI's equity deteriorated from $41.3M in 2024Q1 to -$24.9M by 2026Q2, a swing of $66.2M, as cumulative losses outpaced any capital raises, per quarterly balance sheet data.

The balance sheet is clearly weakening, with total liabilities growing from $163.2M to $203.1M while assets contracted from $204.5M to $178.2M over the same period. This divergence suggests the company is funding operations through debt and other liabilities, not equity, which may indicate a reliance on external financing to sustain growth. The trend implies that without a significant improvement in profitability or a capital infusion, the negative equity position could worsen, potentially straining future financing options.

Debt Load Shifts to Short-Term

Total debt fell from $119.8M in 2024Q1 to $24.6M in 2026Q2, but the current ratio dropped from 3.08 to 1.36, indicating a shift toward short-term obligations, per reported figures.

While the absolute debt reduction appears positive, the concurrent decline in the current ratio from 3.08 to 1.36 suggests that the composition of liabilities has become more immediate, possibly reflecting increased accounts payable or accrued expenses. The D/E ratio is not calculable in recent quarters due to negative equity, but the earlier D/E of 20.18 in 2025Q1 highlights the extreme leverage when equity was minimal. This may indicate that the company is managing its debt by converting long-term obligations into short-term ones, which could heighten refinancing risk if liquidity tightens.

Asset Base Shrinks with Stable Intangibles

Total assets declined from $204.5M to $178.2M over ten quarters, while goodwill remained constant at $7.2M and PPE net fell from $38.4M to $31.8M, per balance sheet data.

The reduction in total assets is driven primarily by a decline in PPE, which may indicate underinvestment in fixed assets or asset sales, consistent with an asset-light model. Goodwill has remained unchanged, suggesting no impairments have been recorded, but the stable goodwill against a shrinking asset base increases its relative weight, potentially raising impairment risk if the company's market value continues to lag. The asset mix appears to be shifting toward more current assets, which could improve liquidity but may also reflect a lack of long-term investment.

Retained Losses Consume Equity

Accumulated deficit grew from -$166.0M to -$283.7M over ten quarters, driving equity from $41.3M to -$24.9M, with no dividends or buybacks, as per financial statements.

The equity deterioration is almost entirely attributable to retained losses, which have grown by $117.7M over the period, far exceeding any capital contributions. The absence of share repurchases or dividends indicates that all cash is being retained for operations, yet the losses continue to erode the equity base. This suggests that the company's growth strategy is heavily dependent on external financing, and the negative equity position may limit its ability to raise additional equity without diluting existing shareholders.

Liquidity Buffer Thins

Cash increased from $36.1M to $41.1M, but the current ratio fell from 3.08 to 1.36, and cash relative to total liabilities dropped from 22% to 20%, per reported data.

While cash has grown modestly, the current ratio has nearly halved, indicating that current liabilities are growing faster than current assets. This suggests that the company's liquidity buffer is thinning relative to its short-term obligations, which could increase vulnerability to cash flow disruptions. The cash position of $41.1M against a quarterly operating loss of around $10M provides a runway of roughly four quarters, but the reliance on working capital swings for positive cash flow in 2026Q2 implies that this runway could be shorter if those swings reverse.

Negative Equity Masks Debt Reduction

Despite a $95.2M reduction in total debt, equity turned negative at -$24.9M, suggesting the debt paydown may have been funded by liquidating assets or increasing other liabilities, per balance sheet data.

The headline improvement in total debt from $119.8M to $24.6M is overshadowed by the fact that equity has swung to a deficit, and total liabilities have actually increased from $163.2M to $203.1M. This implies that the debt reduction may have been achieved by converting debt into other forms of liabilities, such as accounts payable or accrued expenses, rather than through genuine deleveraging. Investors should monitor the composition of liabilities and the sustainability of the current ratio, as the apparent debt reduction may not reflect an improvement in financial health.

STLN — Frequently Asked Questions

Quick answers to the most common questions about buying STLN stock.

What are the total assets of Starling Oncology, Inc. (STLN)?

As of 2025, Starling Oncology, Inc. (STLN) had total assets of $164.7M including $112.7M in current assets.

How much debt does Starling Oncology, Inc. (STLN) have?

Starling Oncology, Inc. (STLN) carries total debt of $103.7M, offset by $33.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Starling Oncology, Inc.?

Starling Oncology, Inc. (STLN) has total shareholders' equity (book value) of $-15.7M ($-0.17 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Starling Oncology, Inc.'s current ratio and liquidity?

Starling Oncology, Inc. (STLN) reported a current ratio of 1.59x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.